These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2020.05.15 Structural Analysis of Small Molecule Inhibitors Binding to TMPRSS2.pdf (935.67 kB)

Structural Analysis of Experimental Drugs Binding to the COVID-19 Target TMPRSS2

submitted on 15.05.2020, 20:51 and posted on 18.05.2020, 11:09 by David Huggins

The emergence of SARS-CoV-2 has prompted a worldwide health emergency. There is an urgent need for therapeutics, both through the repurposing of approved drugs and the development of new treatments. In addition to the viral drug targets, a number of human drug targets have been suggested. In theory, targeting human proteins should provide an advantage over targeting viral proteins in terms of drug resistance, which is commonly a problem in treating RNA viruses. This paper focuses on the human protein TMPRSS2, which supports coronavirus life cycles by cleaving viral spike proteins. The three-dimensional structure of TMPRSS2 is not known and so we have generated models of the TMPRSS2 in the apo state as well as in complex with a peptide substrate and putative inhibitors to aid future work. Importantly, many related human proteases have 80% or higher identity with TMPRSS2 in the S1-S1’ subsites, with plasminogen and urokinase-type plasminogen activator (uPA) having 95% identity. We highlight 376 approved, investigational or experimental drugs targeting S1A serine proteases that may inhibit TMPRSS2. Whilst the presence of a relatively uncommon lysine residue in the S2/S3 subsites means that many serine protease inhibitors may not inhibit TMPRSS2, this is likely to provide a handle for selective targeting. We discuss how experimental drugs targeting related serine proteases might be repurposed as TMPRSS2 inhibitors to treat coronaviruses.


Email Address of Submitting Author


Tri-Institutional Therapeutics Discovery Institute


United States

ORCID For Submitting Author


Declaration of Conflict of Interest

The authors declare no conflicts of interest

Usage metrics